Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress

L Dong¹, CC Jiang¹, RF Thorne², A Croft¹, F Yang¹, H Liu¹, CE de Bock², P Hersey¹ and XD Zhang¹

¹Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Newcastle, New South Wales, Australia and
²Cancer Research Unit, School of Biomedical Sciences, University of Newcastle, Newcastle, New South Wales, Australia

Past studies have shown that upregulation of the anti-apoptotic Bcl-2 family protein Mcl-1 is a major adaptive mechanism of melanoma cells to endoplasmic reticulum (ER) stress, and has an important role in resistance of the cells to apoptosis. In this study, we show that the increase in transcription of Mcl-1 in melanoma cells triggered by pharmacological ER stress inducers is mediated by the transcription factor Ets-1. By incremental deletion analysis of the Mcl-1 promoter, we identified a DNA fragment containing an Ets-1 binding site that is transcriptionally responsive to ER stress. Mutations in the Ets-1 binding site or knockdown of Ets-1 inhibited the increase in Mcl-1, indicating that Ets-1 has a critical role in transcriptional upregulation of Mcl-1. Similar to Mcl-1, Ets-1 was transcriptionally upregulated by ER stress. This was mediated by the IRE1x/XBP-1 branch of the unfolded protein response, as upregulation of Ets-1 was inhibited in melanoma cell lines deficient in IRE1x or XBP-1 established by short hairpin RNA knockdown. Activation of the PI3k/Akt pathway downstream of XBP-1 was also involved, in that inhibition of the pathway blocked upregulation of Ets-1. Inhibition of Ets-1 enhanced ER stress-induced apoptosis in melanoma cell lines and in fresh melanoma isolates, recapitulating the effect of inhibition of Mcl-1. These results reveal a key mechanism by which Mcl-1 is transcriptionally upregulated in melanoma cells by ER stress, and identify Ets-1 as a potential target for inhibition to sensitize melanoma cells to apoptosis.

Oncogene (2011) 30, 3716–3726; doi:10.1038/onc.2011.87; published online 21 March 2011

Keywords: melanoma; Mcl-1; XBP-1; Ets-1; endoplasmic reticulum stress

Introduction

Melanoma continues to increase in incidence in many parts of the world, but there is currently no curative treatment once the disease has spread beyond the primary site. This is largely due to resistance of melanoma cells to induction of apoptosis by available chemotherapeutic drugs and biological reagents (Soengas and Lowe, 2003; Hersey et al., 2006). The anti-apoptotic Bcl-2 family protein Mcl-1 is of particular importance in resistance of melanoma to treatment, in that its expression increases with melanoma progression and is associated with poorer prognosis (Cory and Adams, 2002; Mhaidat et al., 2007; Wang et al., 2007; Zhuang et al., 2007; Jiang et al., 2009a). As a protein with a rapid turn-over rate, Mcl-1 expression is frequently regulated by post-translational mechanisms (Zhong et al., 2005; Warr and Shore, 2008; Schwickart et al., 2010). Nevertheless, an increase in the Mcl-1 protein levels often correlates with an increase in its mRNA levels, mostly due to enhanced transcription (Iglesias-Serret et al., 2003; Warr and Shore, 2008). Several transcription factors including HIF1x and Stat3 are known to regulate Mcl-1 expression in various cell types (Epling-Burnette et al., 2001; Iglesias-Serret et al., 2003; Piret et al., 2005; Isomoto et al., 2005; Wang et al., 2003).

A number of cellular stress conditions, such as nutrient deprivation and alterations in glycosylation status, lead to accumulation of unfolded and/or misfolded proteins in the endoplasmic reticulum (ER) lumen and cause ER stress (Harding et al., 2002; Zhang and Kaufman, 2004; Schroder and Kaufman, 2005). The ER responds by activation of a range of signaling pathways that are collectively termed the ER stress response or the unfolded protein response (UPR) (Harding et al., 2002; Zhang and Kaufman, 2004; Schroder and Kaufman, 2005), which is fundamentally a cyto-protective response, but excessive or prolonged UPR can lead to apoptotic cell death. However, we have found that melanoma cells have largely adapted to ER stress and are resistant to ER stress-induced apoptosis (Hersey and Zhang, 2008; Jiang et al., 2008). In addition, we have shown that upregulation of Mcl-1 is a major adaptive mechanism (Hersey and Zhang, 2008; Jiang et al., 2008). Although transcriptional regulation...
was found to be involved in UPR-mediated upregulation of Mcl-1 (Jiang et al., 2008), the precise mechanism(s) responsible remains to be defined.

E26 transformation-specific sequence (Ets)-1 is a member of the Ets family of transcription factors that have roles in many biologic processes such as cell growth and survival (Dittmer, 2003; Hahne et al., 2008). Increased Ets-1 expression has been reported to correlate with grade of malignancy and poorer prognosis in a number of cancers (Davidson et al., 2001; Span et al., 2002). In melanoma, high levels of Ets-1 are often associated with progression of the disease (Poser and Bosserhoff, 2004; Rothhammer et al., 2004; Torlakovic et al., 2004). The role of Ets-1 in regulation of apoptosis seems to be cell type-dependent, as it protects against apoptosis in some cell types, but induces apoptosis in others (Bories et al., 1995; Sato et al., 2001; Teruyama et al., 2001; Dittmer, 2003). Although the mechanisms involved remain to be better understood, it is known that Ets-1 can regulate the expression of the BH3-only protein Bid in endothelial cells and the expression of Bcl-2 in colon cancer cells (Li et al., 2000; Sato et al., 2001).

We have examined the mechanism responsible for the increase in Mcl-1 at the transcriptional level in melanoma cells upon pharmacological induction of ER stress. We show in this report that transcriptional upregulation of Mcl-1 by ER stress is mediated by Ets-1 that is also upregulated by the IRE1α/XBP-1 branch of the UPR. Moreover, we demonstrate that activation of the PI3k/Akt pathway mediated by XBP-1 is involved in upregulation of Ets-1, and that inhibition of Ets-1 recapitulates, at least in part, the effect of inhibition of Mcl-1 on sensitivity of melanoma cells to ER stress-induced apoptosis.

Results

The region between −205 and −175 of the Mcl-1 promoter is essential for transcriptional upregulation of Mcl-1 in melanoma cells under ER stress

Past studies have shown that a transcriptional increase is involved in upregulation of Mcl-1 in melanoma cells upon ER stress (Jiang et al., 2008). To determine the active region of the Mcl-1 promoter responsible for this, a luciferase reporter containing sequences between −1300 and +10 (pGL3-Mcl-1−1300/+10) (numbers relative to the transcription start site) was constructed and transiently transfected into Mel-CV and MM200 cells (Figure 1a). This region encompasses a number of predicted binding sites for various transcription factors including NF-κB, Stat3, Ets, CREBP and Sp1 (Akgul et al., 2000). Treatment with Tunicamycin (TM) that induces ER stress by inhibition of glycosylation, resulted in significant increases in transcriptional activity of the reporter in both cell lines (P<0.05, two-tailed Student’s t-test) (Figure 1b) (Elbein, 1987). In contrast, exposure to TM did not cause any increase in the transcriptional activity of the luciferase reporter containing the −2600/−1200 upstream region of the Mcl-1 promoter (Supplementary Figure S1). Induction of ER stress by TM was corroborated by the increased levels of GRP78, an indicator of activation of the UPR (Supplementary Figure S2) (Jiang et al., 2008).

To further map the site within the −1300/+10 region responsible for the TM-induced increase in Mcl-1 transcription, a series of incremental deletion reporter constructs contained in this region were analyzed (Figure 1a). As shown in Figure 1b, TM increased transcriptional activity in all the constructs except for pGL3-Mcl-1−175/+10 and pGL3-Mcl-1−65/+10.

---

**Figure 1** The −205/−175 region of the Mcl-1 promoter is essential for transcriptional upregulation of Mcl-1 in melanoma cells under ER stress. (a) A schematic illustration of construction of the luciferase reporter constructs. (b) Mel-CV (left) and MM200 (right) cells were transiently transfected with indicated pGL3-basic based reporter constructs. After 24h, cells were treated with TM (3μM) for a further 16h followed by measurement of the luciferase activity. Bars, s.e. (n = 3).
The shortest fragment that was transcriptionally responsive to TM was pGL3-Mcl-1−205/+10. Therefore, the region between −205 and −175 is required for transcriptional upregulation of Mcl-1 in melanoma cells by ER stress. This was confirmed in experiments with another ER stress inducer thapsigargin (TG) (Supplementary Figure S3) (Sagara and Inesi, 1991).

An Ets binding region located between −205 and −175 of the Mcl-1 promoter is transcriptionally responsive to ER stress

The −205/−175 fragment of the Mcl-1 promoter contains a consensus binding region of the transcription factor c-Rel (Figure 2a) (Akgul et al., 2000), which is known to participate in regulation of cell survival (Chen et al., 2000). We therefore tested if this region has a role in activation of the Mcl-1 promoter by ER stress. Mutation of the region abolished the transcriptional activity of the luciferase reporter after treatment with TM (Figures 2a and b). However, there was no association between c-Rel and the segment spanning from −205 to +10 of the Mcl-1 promoter as shown in chromatin immunoprecipitation (ChIP) assays (Figure 2c), suggesting that transcriptional activation of the −205/−175 fragment by ER stress is not mediated by c-Rel.

Intriguingly, within the c-Rel consensus motif is also a predicted binding site for Ets transcription factors (Akgul et al., 2000). We therefore examined if Ets-1 and -2 are involved in activation of the region. ChIP assays demonstrated that Ets-1, but not Ets-2, bound to the −205/+10 segment, which was enhanced by treatment with TM (Figure 2c). Binding of Ets-1 to the region was also confirmed in electrophoretic mobility shift assay (EMSA) (Figure 2d). The nuclear protein complexed with the labeled probe (the segment from −205 to −175) was diminished with the addition of an antibody against Ets-1, but not an antibody against c-Rel or Ets-2. A supershift in the presence of an anti-Ets1 antibody was not observed in the EMSA assay, presumably due to steric interference between the antibody and oligonucleotide binding, which prevented formation of the antibody–DNA–protein super-complex, as reported previously (Myers et al., 2005; Zhang et al., 2010). Nevertheless, these results suggest that binding of Ets-1 to the −205/−175 region may be responsible for activation of the Mcl-1 promoter in melanoma cells under ER stress.

**Ets-1 is responsible for transcriptional upregulation of Mcl-1 in melanoma cells upon ER stress**

As shown in Figure 3a, TM induced a rapid increase in Ets-1 along with Mcl-1 at the protein level. Similarly,
TM upregulated Ets-1 mRNA levels, which could be inhibited by pretreatment with actinomycin D (Figure 3b), indicating that this was due to a transcriptional increase, rather than a change in the mRNA stability. To confirm transcriptional activation of Ets-1 by TM in melanoma cells, a luciferase reporter containing a 2.5 kb fragment of the Ets-1 promoter was constructed and transiently transfected into Mel-CV and MM200 cells. As shown in Figure 3c, treatment with TM induced significant increases in transcriptional activity of the luciferase reporter in both cell lines (P < 0.05, two-tailed Student’s t-test) (Figures 4a, b and Supplementary Figure S5). Consistently, Ets-1 siRNA significantly inhibited upregulation of the endogenous Mcl-1 mRNA by TM in both cell lines (P < 0.05, two-tailed Student’s t-test) (Figure 4b).

To further confirm the role of Ets-1 in transcriptional upregulation of Mcl-1, we transfected complimentary DNA encoding Ets-1 with or without co-transfection of the luciferase reporters pGL3-Mcl-1–205/+10 into MM200 and Mel-CV cells (Figures 4c and d). Overexpression of Ets-1 markedly enhanced the transcriptional activity of the reporters (P < 0.05, two-tailed Student’s t-test), and as anticipated, also increased the endogenous Mcl-1 mRNA expression in both cell lines (Figure 4d).

Upregulation of Ets-1 by ER stress is mediated by XBP-1
To examine the signaling pathways of the UPR responsible for upregulation of Ets-1 in melanoma cells under ER stress, we established melanoma cell lines

---

Figure 3 ER stress transcriptionally upregulates Ets-1 in melanoma cells. (a) Whole cell lysates from Mel-CV and MM200 cells with or without treatment with TM (3 μM) for indicated periods were subjected to western blot analysis. (b) Mel-CV and MM200 cells with or without pretreatment with actinomycin D (3 μg/ml) for 1 h were treated with TM (3 μM) for 16 h. Total RNA was subjected to qPCR analysis for Ets-1 mRNA expression. The relative abundance of mRNA expression before treatment was arbitrarily designated as 1. (c) A luciferase reporter containing a 2.5 kb fragment of the Ets-1 promoter was constructed and transiently transfected into Mel-CV and MM200 cells. After 24 h, cells were treated with TM (3 μM) for a further 16 h followed by measurement of the luciferase activity. (d) Mel-CV and MM200 cells were treated with TG (1 μM) 16 h. Left panel: total RNA was subjected to qPCR analysis for Ets-1 mRNA expression. The relative abundance of mRNA expression in parental cells was arbitrarily designated as 1. Right: whole cell lysates were subjected to western blot analysis. Bars, s.e. (n = 3).
deficient in expression of the three proximal transducers of the UPR, IRE1α, ATF6 and PERK, with short hairpin RNA (shRNA) knockdown. Figure 5a shows that deficiency in IRE1α or ATF6, but not deficiency in PERK, partially inhibited upregulation of Ets-1 by TM. Consistently, IRE1α or ATF6 deficiency recapitulated partially the effect of siRNA knockdown of Ets-1 on the expression of Mcl-1 at the mRNA level (Figure 5b).

The IRE1α and ATF6 pathways of the UPR converge on XBP-1 (Harding et al., 2002; Zhang and Kaufman, 2004; Schroder and Kaufman, 2005). We therefore examined if XBP-1 has a role in ER stress-induced upregulation of Ets-1 in Mel-CV and MM200 cells, with XBP-1 stably knocked down by shRNA. Figure 5c shows that deficiency in XBP-1 inhibited upregulation of Ets-1 by TM, indicative of a critical role of XBP-1 in upregulation of Ets-1 in melanoma cells under ER stress. Similar to IRE1α or ATF6 deficiency, inhibition of XBP-1 by shRNA recapitulated, in part, the effect of inhibition of Ets-1 by siRNA on the expression of Mcl-1 mRNA (Supplementary Figure S6).

We examined if XBP-1 as a transcription factor is directly responsible for transcriptional upregulation
of Ets-1 in melanoma cells induced by ER stress (Harding et al., 2002; Zhang and Kaufman, 2004; Schroder and Kaufman, 2005). Although examination of the flanking genomic DNA region identified a potential XBP-1 binding site located 1775–1793 bp upstream of the Ets-1 transcription start site (data not shown), there was no binding of XBP-1 to the Ets-1 promoter as shown in both EMSA and ChIP assays (data not shown).

We have previously found that XBP-1 mediates ER stress-induced activation of Akt in melanoma cells, which is known to have a role in regulation of Mcl-1 transcription (Jiang et al., 2009b). We therefore tested the relationship between the activation of Akt and upregulation of Ets-1. As shown in Figure 5d, treatment with the PI3k inhibitor LY294002 blocked activation of Akt and inhibited upregulation of Ets-1 induced by TM. Notably, knockdown of Akt3, the major isoform of Akt in melanoma (Jiang et al., 2009b), reduced the basal levels of Ets-1, suggesting that the PI3k/Akt pathway may have a role in regulating constitutive expression of Ets-1 in melanoma cells (Figure 5e). Although the addition of TM caused a threefold increase in Ets-1 in cells transfected with the control siRNA, there was only a 1.4-fold increase in cells with Akt3 knocked down (Figure 5e), indicating that activation of Akt downstream of XBP-1 is involved in ER stress-induced upregulation of Ets-1.

**Figure 5** XBP-1 mediates upregulation of Ets-1 in melanoma cells under ER stress. (a) Mel-CV and MM200 cells were transfected with the control, IRE1α, ATF6 and PERK shRNA, respectively. Upper panel: whole cell lysates were subjected to western blot analysis. Quantitation of the bands showed that the IRE1α, ATF6 and PERK shRNA inhibited IRE1α, ATF6 and PERK expression by 71 and 70%, 67 and 75%, 76 and 78%, in Mel-CV and MM200 cells, respectively. Lower panel: whole cell lysates were subjected to western blot analysis. (b) Mel-CV and MM200 cells with or without IRE1α and ATF6 knocked down by shRNA, respectively, were treated with TM (3 μM) for 16h. Total RNA was subjected to qPCR analysis for Mcl-1 mRNA expression. The relative abundance of mRNA expression in cells carrying the control shRNA without treatment with TM was arbitrarily designated as 1. (c) Mel-CV and MM200 cells were transfected with the control and XBP-1 shRNA, respectively. Upper panel: whole cell lysates were subjected to western blot analysis. Quantitation of the bands showed that the XBP-1 shRNA inhibited XBP-1 expression by 82 and 85% in Mel-CV and MM200 cells, respectively. Lower panel: whole cell lysates were subjected to western blot analysis. (d) Mel-CV and MM200 cells with or without pretreatment with the PI3k inhibitor LY294002 (20 μM) for 1 h were treated with TM (3 μM) for a further 16h. Whole cell lysates were subjected to western blot analysis. (e) MM200 cells were transfected with the control or Akt3 small RNA interference (siRNA). Upper panel: After 24h, whole cell lysates were subjected to western blot analysis. Quantitation of the bands showed that the Akt3 siRNA inhibited Akt3 expression by 90%. Lower panel: After 24h, cells were treated with TM (3 μM) for a further 16h. Whole cell lysates were subjected to western blot analysis. The intensity of the Ets-1 bands was quantitated and the value in cells transfected with the control siRNA without treatment with TM was arbitrarily designated as 1. The relative expression level of Ets-1 in each sample was depicted below the corresponding blot.
Ets-1 protects melanoma cells from ER stress-induced apoptosis

Because Mcl-1 has a critical role in protection of melanoma cells from ER stress-induced apoptosis (Hersey and Zhang, 2008; Jiang et al., 2008), we examined whether Ets-1 has a similar role. As expected, inhibition of Ets-1 by siRNA rendered Mel-CV and MM200 cells sensitive to apoptosis induced by TM (Figure 6a), which was confirmed by induction of caspase-3 activation (Figure 6b). This sensitization could be blocked by overexpression of Mcl-1, and was not further enhanced in melanoma cells deficient in Mcl-1 (Figures 6c, d and Supplementary Figure S7), suggesting that it was mediated by downregulation of Mcl-1. Similarly, inhibition of Ets-1 also sensitized Mel-CV and MM200 cells to apoptosis induced by TG (Supplementary Figure S8).

We next examined the effect of inhibition of Ets-1 on responses to ER stress in fresh melanoma isolates, which may more closely reflect the in vivo situation where the cells are resistant to ER-stress-induced apoptosis (Nguyen et al., 2001; Jiang et al., 2007). Freshly isolated melanoma cells expressed in general relatively high levels of Ets-1 in comparison with cultured melanocytes (Supplementary Figure S9A). As reported before (Liu et al., 2009; Jiang et al., 2009b), neither TM nor TG induced significant apoptosis in fresh melanoma isolates (<20% apoptotic cells) (Figure 6e). However, when Ets-1 was knocked down, there were significant increases in induction of apoptosis by the compounds (P < 0.05, respectively, two-tailed Student’s t-test) (Figure 6e and Supplementary Figure S9B).

Discussion

The above results extend our previous finding that Mcl-1 is upregulated in melanoma cells under ER stress, by showing that Ets-1 is responsible for the transcriptional increase in Mcl-1 (Jiang et al., 2008). They show that Ets-1 is also upregulated downstream of the IRE1α/XBP-1 branch of the UPR, and that this is associated with activation of the PI3k/Akt pathway. Moreover, the results demonstrate a role of Ets-1 in protection of melanoma cells against ER stress-induced apoptosis, which recapitulates, at least in part, the effect of inhibition of Mcl-1 on sensitivity of melanoma cells to apoptosis induced by ER stress.

Mcl-1 is of particular importance in melanoma, as its expression increases with melanoma progression, is associated with poorer prognosis, and is a key adaptive mechanism of melanoma cells to cellular stress conditions including ER stress (Wang et al., 2007; Zhuang et al., 2007, 2009, 2010). Although Mcl-1 is regulated by a number of signaling pathways (Epling-Burnette et al., 2001; Harding et al., 2002; Iglesias-Serret et al., 2003; Wang et al., 2003; Isomoto et al., 2005; Piret et al., 2005; Warr and Shore, 2008), upregulation of Mcl-1 by the UPR appears to be characteristic of melanoma cells, in that Mcl-1 is commonly downregulated by ER stress in other cell types (Fritsch et al., 2007). Our previous results have shown that upregulation of Mcl-1 in melanoma cells upon ER stress involves a transcriptional increase (Jiang et al., 2008). In the present study, we identified Ets-1 as a key transcription factor that activates Mcl-1 transcription during ER stress in melanoma cells. This was demonstrated by (1) the shortest fragment of the Mcl-1 promoter responsive to ER stress contained a consensus binding site of Ets; (2) Ets-1 bound directly to this site, which was enhanced by induction of ER stress; (3) mutations in this site diminished ER stress-induced activation of the Mcl-1 promoter; and (4), knockdown of Ets-1 inhibited activation of Mcl-1 transcription induced by ER stress, whereas overexpression of Ets-1 enhanced Mcl-1 promoter activity leading to increased Mcl-1 expression. Even though we cannot exclude involvement of changes in the Mcl-1 protein turnover rate, these results clearly demonstrate an important role of Ets-1-mediated increases in Mcl-1 at the transcriptional level in its upregulation induced by ER stress in melanoma cells.

Ets-1 is expressed at high levels in many types of cancers, and is involved in many biological processes in cancer cells such as cell growth and survival (Davidson et al., 2001; Span et al., 2002; Dittmer, 2003; Hahne et al., 2008). In melanoma, the levels Ets-1 were similarly found to be higher than those in benign melanocytic lesions and melanocytes, and to increase with progression of the disease (Poser and Bosserhoff, 2004; Rothhammer et al., 2004; Torlakovic et al., 2004). Consistently, the results in this study also showed that Ets-1 was commonly expressed at high levels in fresh melanoma isolates. Although the role of Ets-1 in regulation of apoptosis may vary between different cell types (Bories et al., 1995; Teruyama et al., 2001), our finding that Ets-1 was responsible for transcriptional upregulation of Mcl-1 in melanoma cells subjected to ER stress indicates that it is critical in protection of melanoma cells against ER stress-induced apoptosis. It is conceivable that, like Mcl-1, Ets-1 may also contribute to resistance of melanoma cells to apoptosis induced by agents other than those that induce ER stress (Liu et al., 2009; Jiang et al., 2009c).

An important finding of this study is upregulation of Ets-1 by ER stress in melanoma cells. This appeared to be due to a transcriptional mechanism. Upregulation of Ets-1 by ER stress was partially inhibited in melanoma cells deficient in IRE1α or ATF6, indicating that these branches of the UPR are involved in the ER stress-triggered increase in Ets-1 in melanoma cells. On activation, the RNase activity of IRE1α cleaves XBP1 mRNA, generating a splicing variant that encodes a potent transcription factor (Harding et al., 2002; Zhang and Kaufman, 2004; Schroder and Kaufman, 2005). As a transcription factor, activated ATF6 activates transcription of UPR target genes including XBP1 (Harding et al., 2002; Zhang and Kaufman, 2004; Schroder and Kaufman, 2005). The convergence of the IRE1α and ATF6 pathways on XBP1 suggests that XBP1 may be involved in upregulation of Ets-1 by the UPR. This was validated in melanoma cells with XBP1
knocked down by shRNA. These results were in line with the essential role of XBP-1 in upregulation of Mcl-1, as reported previously (Jiang et al., 2008).

Consistent with our previous finding that activation of the PI3k/Akt pathway by XBP-1 is involved in upregulation of Mcl-1 by the UPR in melanoma cells (Jiang et al., 2009b), we found in this study that activation of PI3k/Akt downstream of XBP-1 had a role in ER stress-induced upregulation of Ets-1. The mechanism(s) by which the PI3K/Akt pathway mediates regulation of Ets-1 remains to be determined, but it is known that activation of Akt increases the expression of
the transcription factors AP1 and AP2 that regulate Ets-1 transcription (Majeacuterus et al., 1992; Dittmer, 2003). Some other transcription factors that have been shown to transcriptionally upregulate Ets-1 include Sp1, HIF-1 and Ets-1 itself (Majeacuterus et al., 1992; Dittmer, 2003; Hahne et al., 2008).

Our finding that Ets-1 has a role in protection of freshly isolated melanoma cells against ER stress-induced apoptosis is significant, as they may reflect more closely responses of melanoma cells to ER stress in vivo (Nguyen et al., 2001; Jiang et al., 2007). The relatively high levels of Ets-1 expression is conceivably a consequence of activation of the UPR (Zhuang et al., 2009; Jiang et al., 2009c), and a means of adaptation to chronic ER stress conditions encountered by melanoma cells in vivo. Collectively, results in this study reveal a key mechanism responsible for transcriptional upregulation of Mcl-1 by ER stress in melanoma cells, and identify upregulation of Ets-1 as part of the adaptive mechanism of the cells to ER stress. Ets-1 may therefore be a potential target for the treatment of melanoma in combination with therapeutics that induce ER stress.

### Materials and methods

**Cell culture and reagents**

Human melanoma cell lines Me4405, ME1007, Mel-CV, Sk-Mel-28, Sk-Mel-110 and MM200 have been described previously and were cultured in Dulbecco’s modified Eagle’s medium containing 5% fetal calf serum (Commonwealth Serum Laboratories, Melbourne, VIC, Australia) (Gillespie et al., 2003). Some other transcription factors that have been previously and were cultured in Dulbecco’s modified Eagle’s medium containing 5% fetal calf serum (Commonwealth Serum Laboratories, Melbourne, VIC, Australia) (Gillespie et al., 2003). DNA for cell line authentication was extracted from all the cell lines while cultured for this study. Individual cell line authentication was confirmed using the AmpFISTR Identifier PCR Amplification Kit from Applied Biosystems (Mulgrave, VIC, Australia) and GeneMarker v1.91 software (SoftGenetics LLC, State College, PA, USA). A panel of 16 markers was tested, and each cell line had a distinct individual set of markers present. TM and TG were purchased from Sigma-Aldrich (Castle Hill, NSW, Australia). The PI3 K inhibitor, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002), was purchased from Calbiochem (Kilsyth, VIC, Australia). The mouse monoclonal antibodies against Mcl-1 and the rabbit polyclonal antibodies (Abs) against Ets-1, Ets-2, c-Rel, BCL-XL, GRP78, IRE1α, ATF6 and PERK were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The rabbit antibodies against Akt, phospho-Akt (Ser473) and the rabbit polyclonal antibodies (Abs) against Ets-1, Ets-2, c-Rel, XBP-1, GRP78, IRE1α, ATF6 and PERK were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The rabbit antibodies against Akt, phospho-Akt (Ser473) and the rabbit polyclonal antibodies (Abs) against Ets-1, Ets-2, c-Rel, XBP-1, GRP78, IRE1α, ATF6 and PERK were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). A panel of 16 markers was tested, and each cell line had a distinct individual set of markers present. TM and TG were purchased from Sigma-Aldrich (Castle Hill, NSW, Australia). The PI3 K inhibitor, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002), was purchased from Calbiochem (Kilsyth, VIC, Australia). The mouse monoclonal antibodies against Mcl-1 and the rabbit polyclonal antibodies (Abs) against Ets-1, Ets-2, c-Rel, BCL-XL, GRP78, IRE1α, ATF6 and PERK were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The rabbit antibodies against Akt, phospho-Akt (Ser473) were from Cell Signaling Technology (Danvers, MA, USA). The rabbit polyclonal antibodies against caspase-3 were from Stressgen Biotechnologies (Victoria, BC, Canada).

**Fresh melanoma isolates**

Isolation of melanoma cells from fresh surgical specimens was carried out as described previously (Jiang et al., 2010).

**Apoptosis**

Quantitation of apoptotic cells was carried out using propidium iodide as described elsewhere (Jiang et al., 2010; Yang et al., 2010).

**Western blot analysis**

Western blot analysis was carried out as described previously (Jiang et al., 2010; Yang et al., 2010). The intensity of bands was quantitated relative to corresponding GAPDH bands with the Bio-Rad VersaDoc image system (Bio-Rad, Regents Park, NSW, Australia).

**Quantitative reverse transcription and real-time–PCR**

Quantitative reverse transcription and real-time PCR was performed as described previously (Jiang et al., 2010; Yang et al., 2010). The primers used for PCR are as follows: ETS1: sense, 5′-GTCGCTGGTAAAACCTCGG-3′, anti-sense, 5′-CAGCAGGAGGATGACAGG-3′; Mcl-1: sense, 5′-CTTACCAGCCGGTTGGG-3′, anti-sense, 5′-GGTTCATGACCTTTTCGGG-3′; c-Rel: sense, 5′-TTGGACAAAGAAGCCAGAC-3′, anti-sense, 5′-CAGGAGGAGAGACGTG-3′.

**siRNA**

The siRNA constructs used were obtained as the siGENOME SMARTpool reagents (Dharmacon, Lafayatte, CO, USA), c-Rel siGENOME SMARTpool (M-004768-01-0010), Ets-1 siGENOME SMARTpool (M-003878-00-0010), AKT3 siGENOME SMARTpool (M-003002-02-0010), and siGENOME ME Non-targeting siRNA pool (D-001206-13-20). Transfection of siRNA pools was carried out as described previously (Jiang et al., 2010; Yang et al., 2010).

**shRNA**

Sigma MISSION Lentiviral Transduction Particles for shRNA-mediated knockdown of Mcl-1 were purchased from Sigma-Aldrich and used as described previously (Castle Hill, NSW, Australia) (Jiang et al., 2008).

**Luciferase-reporter constructs**

The Mcl-1 promoter sequence from 1300 bp upstream to 10 bp downstream of the human Mcl-1 gene transcription start site was cloned by genomic PCR using human genomic DNA as a template. Deletions of the promoter were generated by PCR with 5′ primers and a fixed 3′ primer. The sequences of these forward primers were: 5′-GCTAGCAACTGATACATGTC TTGTAATCT-3′(1300/10), 5′-GCTAGCATTTTGAGTTAAA AACCTCTGGCG-3′(300/10), 5′-GCTAGCTCGGAGCGGCCGT TAC-3′(-224/10), 5′-GCTAGCCAGACCTCCTCGA AGACCCG-3′(-205/10), 5′-GCTAGCTGAGGCCCCGGCT CAGG-3′(-175/10), 5′-GCTAGCCGTGCGCCCGCTTCCCC TTTTT-3′(-65/10). The reverse primer was: 5′-CCCCAAAGCT GTCCATCGGGGTGCGCCCGACGAC-3′. Mutagenesis of the Ets1 binding site was performed by PCR using oligonucleotides carrying mutations at the presumed Ets1 core recognition sites, in combination with the anti-sense primer (-10). These Mcl-1 promoter fragments were cloned into promoter-less luciferase reporter plasmid pGL3-Basic Luciferase Vector (Promega, Madison, WI, USA). A 2.5 kb fragment of the Ets1 promoter was subcloned into the pGL3-Basic Luciferase Vector as described (Jorcyk et al., 1997; Wagner et al., 2008). Cells were transiently transfected with luciferase constructs together with the pRL-TK vector as a control for transfection efficiency. The luciferase activity was measured using the Dual Luciferase Reporter Assay System (Promega) by Synergy 2 multi-detection microplate reader (BioTek, Vinooski, VT, USA).

**EMSA**

Nuclear extracts were prepared using NE-PER Nuclear Extraction Reagents Kit (Pierce, Rockford, IL, USA). The DNA–protein binding was detected using the Light-Shift chemiluminescent EMSA kit (Pierce). Binding reactions were performed by adding 2 μg of the nuclear extracts to a mixture...
References

Akgul C, Turner PC, White MR, Edwards SW. (2000). Functional analysis of the human MCL-1 gene. Cell Mol Life Sci 57: 684–691.

Bories JC, Willerford DM, Grévin D, Davidson L, Camus A, Martin P et al. (1995). Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the Ets-1 proto-oncogene. Nature 377: 635–638.

Chen C, Edelstein LC, Gélinas C., (2000). The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 20: 2687–2695.

Cory S, Adams JM.. (2002). The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2: 647–656.

Davidson B, Risberg B, Goldberg I, Neslund JM, Berner A, Tropcé CG et al. (2001). Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome. Am J Surg Pathol 25: 1493–1500.

Dittmer J. (2003). The biology of the Ets proto-oncogene. Mol Cancer 2: 29.

Elbein AD. (1987). Inhibitors of the biosynthesis and processing of N-linked oligosaccharide chains. Annu Rev Biochem 56: 497–534.

Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R et al. (2001). Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107: 351–362.

Fritsch RM, Schneider G, Saur D, Scheibl M, Schmid RM.. (2007). Translational repression of MCL-1 couples stress-induced eIF2alpha phosphorylation to mitochondrial apoptosis initiation. J Biol Chem 282: 22551–22562.

Gillespie S, Zhang XD, Hersey P. (2005). Variable expression of protein kinase C epsilon in human melanoma cells regulates sensitivity to TRAIL-induced apoptosis. Mol Cancer Ther 4: 668–676.

Hahne JC, Okuducu AF, Sahin A, Fafeur V, Kirakidis S, Wernert N. (2008). The transcription factor ETS-1: its role in tumour development and strategies for its inhibition. Minireview. Exp Mol Med 40: 1095–1105.

Harding HP, Calfon M, Urano F, Novoa I, Ron D. (2002). Transcriptional and translational control in the mammalian unfolded protein response. Annu Rev Cell Dev Biol 18: 575–599.

Hersey P, Zhang L, Zhang XD. (2005). Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model. Int Rev Cytol 251: 131–158.

Hersey P, Zhang XD. (2008). Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma. Pigment Cell Melanoma Res 21: 358–367.

Iglesias-Serret D, Piquè M, Gil J, Pons G, López JM. (2003). Transcriptional and translational control of Mcl-1 during apoptosis. Arch Biochem Biophys 417: 141–152.

Isomoto H, Kobayashi S, Wernerb NG, Bronk SF, Guicciardi ME, Frank DA et al. (2005). Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 42: 1329–1338.

Jiang CC, Wroblewski D, Yang F, Hersey P, Zhang XD. (2009a). Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax. Neoplasia 11: 945–955.

Jiang CC, Lucas K, Avery-Kiejda KA, Wade M, deBock CE, Thorne RF et al. (2008). Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. Cancer Res 68: 6708–6717.

Jiang CC, Yang F, Thorne RF, Zhu BK, Hersey P, Zhang XD. (2009b). Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt. Neoplasia 11: 436–447.

Jiang CC, Chen LH, Gillespie S, Wang YF, Kiejda KA, Zhang XD et al. (2007). Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis. Cancer Res 67: 9750–9761.

Jiang CC, Mao ZG, Avery-Kiejda KA, Wade M, Hersey P, Zhang XD. (2009c). Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells. Carcinogenesis 30: 197–204.

Jiang CC, Lai F, Tay KH, Croft A, Rizos H, Becker TM et al. (2010). Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of BimS. Cell Death Dis 1: e69; doi:10.1038/cddis.2010.48.

Jorczyk CL, Garrett LJ, Maroulakou IG, Watson DK, Green JE. (1997). Multiple regulatory regions control the expression of Ets-1 in the developing mouse: vascular expression conferred by intron I. Cell Mol Biol (Noisy-le-grand) 43: 211–225.

Li R, Pei H, Watson DK, Papas TS. (2000). EAP1/Daxx interacts with ETS1 and represses transcriptional activation of ETS1 target genes. Oncogene 19: 745–753.

Liu H, Jiang CC, Lavis CJ, Croft A, Dong L, Tseng HY et al. (2009). 2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2. Mol Cancer 8: 122.
Majeacuterus MA, Bibollet-Ruche F, Telliez JB, Wasylyk B, Bailleul B. (1992). Serum, AP-1 and Ets-1 stimulate the human ets-1 promoter. *Nucleic Acids Res* 20: 2699–2703.

Mhaidat NM, Zhang XD, Jiang CC, Hersey P. (2007). Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. *Clin Cancer Res* 13: 1308–1314.

Myers E, Hill AD, Kelly G, McDermott EW, O’Higgins NJ, Buggy Y, Piret JP, Minet E, Cosse JP, Ninane N, Debacq C, Raes M, Nguyen T, Zhang XD, Hersey P. (2001). Relative resistance of fresh melanoma cells to apoptosis: gain of FLIP (FLICE-inhibitory protein) expression is associated with disease progression and is associated with poor outcome. *Oncogene* 20: 3662–3672.

Rothhammer T, Hahne JC, Florin A, Poser I, Soncin F, Wernert N, Sagara Y, Inesi G. (1991). Inhibition of the sarcoplasmic reticulum Ca2+ transport ATPase by thapsigargin at subnanomolar concentrations. *J Biol Chem* 266: 13503–13506.

Nguyen T, Zhang XD, Hersey P. (2001). Relativity of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. *Clin Cancer Res* 7(3 Suppl): 966s–973s.

Piret JP, Minet E, Cosse JP, Ninane N, Debaaq C, Raes M et al. (2005). Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. *J Biol Chem* 280: 9336–9344.

Poser I, Bosserhoff AK. (2004). Transcription factors involved in development and progression of malignant melanoma. *Histol Histopathol* 19: 173–188.

Rothhammer T, Hahne JC, Florin A, Poser I, Soncin F, Wernert N et al. (2004). The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. *Cell Mol Life Sci* 61: 118–128.

Sagara Y, Inesi G. (1991). Inhibition of the sarcoplasmic reticulum Ca2+ transport ATPase by thapsigargin at subnanomolar concentrations. *J Biol Chem* 266: 13503–13506.

Sato Y, Teruyama K, Nakano T, Oda N, Abe M, Tanaka K et al. (2001). Role of transcription factors in angiogenesis: Ets-1 promotes angiogenesis as well as endothelial apoptosis. *Am NY Acad Sci* 947: 117–123.

Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM et al. (2010). Deubiquitinase USP9X stabilizes MCL1 and promotes tumor cell survival. *Nature* 463: 103–107.

Schroder M, Kaufman RJ. (2005). The mammalian unfolded protein response. *Annu Rev Biochem* 74: 739–789.

Soengas MS, Lowe SW. (2003). Apoptosis and melanoma chemoresistance. *Oncogene* 22: 3138–3151.

Span PN, Manders P, Heuel JJ, Thomas CM, Bosch RR, Beex LV et al. (2002). Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. *Oncogene* 21: 8506–8509.

Teruyama K, Abe M, Nakano T, Iwasaka-Yagi C, Takahashi S, Yamada S et al. (2001). Role of transcription factor Ets-1 in the apoptosis of human vascular endothelial cells. *J Cell Physiol* 188: 243–252.

Törkölökovic EE, Bilalovic N, Nesland JM, Törkölökovic G, Florenes VA. (2004). Ets-1 transcription factor is widely expressed in benign and malignant melanocytes and its expression has no significant association with prognosis. *Mod Pathol* 17: 1400–1406.

Wagner N, Michiels JF, Scheidl A, Wagner KD. (2008). The Wilms’ tumour suppressor WT1 is involved in endothelial cell proliferation and migration: expression in tumour vessels in vivo. *Oncogene* 27: 3662–3672.

Wang YF, Jiang CC, Kiejda KA, Gillespie S, Zhang XD, Hersey P. (2007). Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. *Clin Cancer Res* 13: 4934–4942.

Wang JM, Lai MZ, Yang-Yen HF. (2003). Interleukin-3-stimulation of mcl-1 gene transcription involves activation of the PU.1 transcription factor through a p38 mitogen-activated protein kinase-dependent pathway. *Mol Cell Biol* 23: 1896–1909.

Warr MR, Shore GC. (2008). Unique biology of Mcl-1: therapeutic opportunities in cancer. *Curr Mol Med* 8: 138–147.

Yang F, Tay KH, Dong L, Thorne RF, Jiang CC, Yang E et al. (2010). Cystatin B inhibition of TRAIL-induced apoptosis is associated with the protection of FLIP(L) from degradation by the E3 ligase itch in human melanoma cells. *Cell Death Differ* 17: 1354–1367.

Zhang K, Kaufman RJ. (2004). Signaling the unfolded protein response from the endoplasmic reticulum. *J Biol Chem* 279: 25935–25938.

Zhang Z, Kobayashi S, Borczuk AC, Leidner RS, Laframboise T, Levine AD et al. (2010). Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. *Carcinogenesis* 31: 577–586.

Zhong Q, Gao W, Du F, Wang X. (2005). Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. *Cell* 121: 1085–1095.

Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF et al. (2007). Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. *Mod Pathol* 20: 416–426.

Zhuang L, Scolyer RA, Lee CS, McCarthy SW, Cooper WA, Zhang XD et al. (2009). Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma. *Histopathology* 54: 462–470.

Zhuang L, Scolyer RA, Murali R, McCarthy SW, Zhang XD, Thompson JF et al. (2010). Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. *Mod Pathol* 23: 45–53.

This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/